SecBot SecBot
8-K ·Filed Jul 27, 2026

SRPT

Sarepta Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed3mo ago SEC0001193125-26-316995
Actionable Insight • Neutral

CEO succession is routine and non-material for stock performance. Monitor any strategic shifts or pipeline updates under Severino's leadership, particularly in Duchenne programs and siRNA pipeline. The orderly transition (Ingram advising through year-end) reduces execution risk.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$15.89
T+0 close · Jul 27, 2026 · via day close
Latest settled
+11.58%
T+60 · $17.73
Vs SPY
+7.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 27 $15.89entry
  2. T+1 · 4mo ago −2.89%α −3.13% · $15.43
  3. T+5 · 4mo ago −6.48%α −7.56% · $14.86
  4. T+20 · 3mo ago +14.10%α +10.80% · $18.13
  5. T+60 · 28d ago +11.58%α +7.87% · $17.73
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sarepta Therapeutics appointed Michael Severino, M.D., as CEO effective July 28, 2026, succeeding Doug Ingram who is retiring and will serve as a consultant through December 31, 2026. Severino brings extensive R&D and leadership experience from AbbVie and Tessera Therapeutics, and will receive a compensation package including a $1.18M base salary, 110% target bonus, and a $35M sign-on equity grant.

Key Facts

  • Michael Severino appointed CEO and Class I director effective July 28, 2026
  • Douglas Ingram retires as CEO and board member, enters consulting agreement at $15,000/month through Dec 31, 2026
  • Severino's base salary: $1,180,000 per year; target bonus: 110% of base salary
  • Sign-on equity grant: ~$35,000,000 in RSUs and premium-priced stock options vesting over 4 years
  • Severino previously served as CEO of Tessera Therapeutics and Vice Chairman/President at AbbVie

Financial Impact

CEO compensation: $1,180,000 base salary, ~$35,000,000 sign-on equity grant; outgoing CEO consulting fee: $15,000/month

executive compensationmanagement continuity

Risk Factors

  • Execution risk during leadership transition
  • Potential strategic pivot away from current Duchenne-focused strategy

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
38% bullish (34 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (SRPT), Batch item 10001193125-26-316995
Document: d101719d8k.htm0001193125-26-316995
Document: d101719dex102.htm0001193125-26-316995
Document: d101719dex991.htm0001193125-26-316995
Document: 0001193125-26-316995-index-headers.html0001193125-26-316995
Document: 0001193125-26-316995-index.html0001193125-26-316995
Document: 0001193125-26-316995.txt0001193125-26-316995
8-K Filing (SRPT), Batch item 80001193125-26-316995

US Market Status

Market Closed · Opens in 9h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 27, 2026